Cellectar Biosciences Inc (NAS:CLRB)
$ 0.3052 -0.9748 (-76.16%) Market Cap: 52.83 Mil Enterprise Value: 35.58 Mil PE Ratio: 0 PB Ratio: 33.68 GF Score: 30/100

Cellectar Biosciences Inc at ROTH Conference Transcript

Mar 13, 2023 / 12:30PM GMT
Release Date Price: $1.56 (-3.11%)
Jonathan Aschoff
ROTH Capital Partners - Analyst

With me now, we have Jim Caruso, the CEO of Cellectar Biosciences. Welcome, Jim.

Jim Caruso
Cellectar Biosciences, Inc. - President, CEO, & Director

It's a pleasure to be here, Jonathan. And thank you to all of you for attending this session, very much appreciate it.

Questions & Answers

Jonathan Aschoff
ROTH Capital Partners - Analyst

It's great to have you here. So what prompted you to target a pivotal trial in Waldenstrom's macroglobulinemia -- that's a big mouthful; we'll call it WM -- with your lead drug, iopofosine?

Jim Caruso
Cellectar Biosciences, Inc. - President, CEO, & Director

Now that's a great place for us to start. We were in the midst of a Phase 2 trial and a basket study for non-Hodgkin's lymphomas. And we came across a really interesting signal with WM. In fact, of the first six patients that we dosed with iopofosine I 131, we had a 100% response rate.

In fact, the very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot